Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients

• Status: Recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: All

Summary

This randomized controlled clinical trial will compare the eradication efficacy of bismuth quadruple therapy containing clarithromycin+metronidazole, clarithromycin+levofloxacin, or metronidazole+levofloxacin for Helicobacter pylori first-line treatment in penicillin-allergic patients. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Zhongshan Hospital
• Treatments: Bismuth; Clarithromycin; Levofloxacin; Metronidazole; Ofloxacin; Potassium Citrate; Rabeprazole

Criteria

Inclusion Criteria:

• Participate in the trial voluntarily, fully understand the trial, and sign the informed consent form (ICF).

• 18-75 years old on the day of signing the ICF.

• Helicobacter pylori infection confirmed by 13C-urea breath test or rapid urease test.

• Have not received Helicobacter pylori eradication treatment before.

• allergic to penicillin.

Exclusion Criteria:

• Have received Hp eradication treatment.

• Patients with severe heart, lung, kidney, liver, blood, nerve, endocrine, and psychiatric diseases.

• Subjects or guardians refused to participate in the trial.

• Alcohol and/or drugs Abuse (addiction or dependence) or poor compliance with doctor's judgment.

• Have taken antibiotics, bismuth, proton pump inhibitors or Chinese traditional medicine 4 weeks before treatment.

• Pregnant or lactating women.

• Active peptic ulcer.

• allergic to drugs used in the trial.

• any other circumstances that are not suitable for recruitment.